Literature DB >> 22086665

Medication-assisted treatment research with criminal justice populations: challenges of implementation.

Michael S Gordon1, Timothy W Kinlock, Patrice M Miller.   

Abstract

Creating, implementing and evaluating substance abuse interventions, especially medication-assisted treatments, for prisoners, parolees, and probationers with histories of heroin addiction is an especially challenging endeavor because of the difficulty in coordinating and achieving cooperation among diverse criminal justice, substance abuse treatment, research, and social service agencies, each with its own priorities and agenda. In addition, there are special rules that must be followed when conducting research with criminal justice-involved populations, particularly prisoners. The following case studies will explore the authors' experience of over 10 years conducting pharmacotherapy research using methadone, buprenorphine, and naltrexone with criminal justice populations. The major obstacles and how they were overcome are presented. Finally, recommendations are provided with regard to implementing and conducting research with criminal justice populations. 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22086665      PMCID: PMC3243915          DOI: 10.1002/bsl.1015

Source DB:  PubMed          Journal:  Behav Sci Law        ISSN: 0735-3936


  32 in total

1.  Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.

Authors:  L Amass; J B Kamien; S K Mikulich
Journal:  Drug Alcohol Depend       Date:  2000-02-01       Impact factor: 4.492

2.  Correlates of treatment follow-up difficulty.

Authors:  Susanna Nemes; Eric Wish; Brook Wraight; Nena Messina
Journal:  Subst Use Misuse       Date:  2002-01       Impact factor: 2.164

3.  Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans.

Authors:  L Amass; W K Bickel; J P Crean; J Blake; S T Higgins
Journal:  Psychopharmacology (Berl)       Date:  1998-04       Impact factor: 4.530

4.  Naltrexone pharmacotherapy for opioid dependent federal probationers.

Authors:  J W Cornish; D Metzger; G E Woody; D Wilson; A T McLellan; B Vandergrift; C P O'Brien
Journal:  J Subst Abuse Treat       Date:  1997 Nov-Dec

5.  Persistence of drug use during imprisonment: relationship of drug type, recency of use and severity of dependence to use of heroin, cocaine and amphetamine in prison.

Authors:  John Strang; Michael Gossop; Joan Heuston; John Green; Christopher Whiteley; Anthony Maden
Journal:  Addiction       Date:  2006-08       Impact factor: 6.526

6.  Risk of death in prisoners after release from jail.

Authors:  L M Stewart; C J Henderson; M S T Hobbs; S C Ridout; M W Knuiman
Journal:  Aust N Z J Public Health       Date:  2004-02       Impact factor: 2.939

Review 7.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2004

8.  A Study of Methadone Maintenance For Male Prisoners: 3-Month Postrelease Outcomes.

Authors:  Timothy W Kinlock; Michael S Gordon; Robert P Schwartz; Kevin E O'Grady
Journal:  Crim Justice Behav       Date:  2008

9.  Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial.

Authors:  Stephen Magura; Joshua D Lee; Jason Hershberger; Herman Joseph; Lisa Marsch; Carol Shropshire; Andrew Rosenblum
Journal:  Drug Alcohol Depend       Date:  2008-10-18       Impact factor: 4.492

Review 10.  Meta-analysis of drug-related deaths soon after release from prison.

Authors:  Elizabeth L C Merrall; Azar Kariminia; Ingrid A Binswanger; Michael S Hobbs; Michael Farrell; John Marsden; Sharon J Hutchinson; Sheila M Bird
Journal:  Addiction       Date:  2010-06-23       Impact factor: 6.526

View more
  13 in total

1.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

2.  Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators.

Authors:  Maxim Polonsky; Julia Rozanova; Lyuba Azbel; Chethan Bachireddy; Jacob Izenberg; Tetiana Kiriazova; Sergii Dvoryak; Frederick L Altice
Journal:  AIDS Behav       Date:  2016-12

3.  Initiation of buprenorphine during incarceration and retention in treatment upon release.

Authors:  Nickolas Zaller; Michelle McKenzie; Peter D Friedmann; Traci C Green; Samuel McGowan; Josiah D Rich
Journal:  J Subst Abuse Treat       Date:  2013-03-27

4.  Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.

Authors:  Michael S Gordon; Frank J Vocci; Terrence T Fitzgerald; Kevin E O'Grady; Charles P O'Brien
Journal:  Contemp Clin Trials       Date:  2016-12-20       Impact factor: 2.226

5.  A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Kevin E O'Grady; Terrence T Fitzgerald; Frank J Vocci
Journal:  Drug Alcohol Depend       Date:  2017-01-11       Impact factor: 4.492

6.  Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.

Authors:  Traci R Rieckmann; Amanda J Abraham; Anne E Kovas; Bentson H McFarland; Paul M Roman
Journal:  Addict Behav       Date:  2014-02-07       Impact factor: 3.913

7.  Assessing factors associated with discharge from opioid agonist therapy due to incarceration in the United States.

Authors:  Phillip L Marotta; Kristi L Stringer; Amar D Mandavia; Alissa Davis; Leo Beletsky; Tim Hunt; Dawn Goddard-Eckrich; Elwin Wu; Louisa Gilbert; Nabila El-Bassel
Journal:  J Addict Dis       Date:  2019-12-10

8.  Buprenorphine Treatment for Probationers and Parolees.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Kathryn A Couvillion; Laura J Sudec; Kevin E O'Grady; Frank J Vocci; Hamin Shabazz
Journal:  Subst Abus       Date:  2014-04-04       Impact factor: 3.716

Review 9.  Confronting the HIV, Tuberculosis, Addiction, and Incarceration Syndemic in Southeast Asia: Lessons Learned from Malaysia.

Authors:  Gabriel J Culbert; Veena Pillai; Joseph Bick; Haider A Al-Darraji; Jeffrey A Wickersham; Martin P Wegman; Alexander R Bazazi; Enrico Ferro; Michael Copenhaver; Adeeba Kamarulzaman; Frederick L Altice
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-24       Impact factor: 4.147

10.  Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners.

Authors:  Sandra A Springer; Jingjun Qiu; Ali Shabahang Saber-Tehrani; Frederick L Altice
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.